244 related articles for article (PubMed ID: 27704550)
1. Recommended strategies for the oral administration of paediatric medicines with food and drinks in the context of their biopharmaceutical properties: a review.
Martir J; Flanagan T; Mann J; Fotaki N
J Pharm Pharmacol; 2017 Apr; 69(4):384-397. PubMed ID: 27704550
[TBL] [Abstract][Full Text] [Related]
2. Co-administration of Paediatric Medicines with Food and Drinks in the Context of Their Physicochemical Properties-a Global Perspective on Practices and Recommendations.
Martir J; Flanagan T; Mann J; Fotaki N
AAPS J; 2020 Mar; 22(2):54. PubMed ID: 32133550
[TBL] [Abstract][Full Text] [Related]
3. Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance: Part 1-Effects on Solubility of Poorly Soluble Drugs.
Martir J; Flanagan T; Mann J; Fotaki N
AAPS PharmSciTech; 2020 Jun; 21(5):177. PubMed ID: 32592045
[TBL] [Abstract][Full Text] [Related]
4. Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance Part 2: Dissolution of Montelukast Sodium and Mesalazine Formulations.
Martir J; Flanagan T; Mann J; Fotaki N
AAPS PharmSciTech; 2020 Oct; 21(7):287. PubMed ID: 33063245
[TBL] [Abstract][Full Text] [Related]
5. Physicochemical characterisation of fluids and soft foods frequently mixed with oral drug formulations prior to administration to children.
Kersten E; Barry A; Klein S
Pharmazie; 2016 Mar; 71(3):122-7. PubMed ID: 27183705
[TBL] [Abstract][Full Text] [Related]
6. Barriers to administering non-oral formulations in a paediatric population: A semi-structured interview study.
Venables R; Batchelor H; Stirling H; Marriott J
Int J Pharm; 2016 Jan; 497(1-2):12-7. PubMed ID: 26611666
[TBL] [Abstract][Full Text] [Related]
7. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.
Batchelor HK; Kendall R; Desset-Brethes S; Alex R; Ernest TB;
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):833-42. PubMed ID: 23665448
[TBL] [Abstract][Full Text] [Related]
8. Evidence of acceptability of oral paediatric medicines: a review.
Mistry P; Batchelor H;
J Pharm Pharmacol; 2017 Apr; 69(4):361-376. PubMed ID: 27524471
[TBL] [Abstract][Full Text] [Related]
9. Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products - a PEARRL review.
Guimarães M; Statelova M; Holm R; Reppas C; Symilllides M; Vertzoni M; Fotaki N
J Pharm Pharmacol; 2019 Apr; 71(4):603-642. PubMed ID: 29971768
[TBL] [Abstract][Full Text] [Related]
10. In vitro models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
[TBL] [Abstract][Full Text] [Related]
11. Determination of formulation factors that affect oral medicines acceptability in a domiciliary paediatric population.
Venables R; Batchelor H; Hodson J; Stirling H; Marriott J
Int J Pharm; 2015 Mar; 480(1-2):55-62. PubMed ID: 25601436
[TBL] [Abstract][Full Text] [Related]
12. Changes in availability of paediatric medicines in Australia between 1998 and 2002.
Chui J; Tordoff J; Reith D
Br J Clin Pharmacol; 2005 Jun; 59(6):736-42. PubMed ID: 15948941
[TBL] [Abstract][Full Text] [Related]
13. Exploring paediatric oral suspension development: Challenges, requirements, and formulation advancements.
Gaikwad SS; Morales JO; Lande NB; Catalán-Figueroa J; Laddha UD; Kshirsagar SJ
Int J Pharm; 2024 May; 657():124169. PubMed ID: 38688428
[TBL] [Abstract][Full Text] [Related]
14. Paediatric oral biopharmaceutics: key considerations and current challenges.
Batchelor HK; Fotaki N; Klein S
Adv Drug Deliv Rev; 2014 Jun; 73():102-26. PubMed ID: 24189013
[TBL] [Abstract][Full Text] [Related]
15. Paediatric biopharmaceutics classification system: current status and future decisions.
Batchelor H;
Int J Pharm; 2014 Aug; 469(2):251-3. PubMed ID: 24602991
[TBL] [Abstract][Full Text] [Related]
16. Food for thought: formulating away the food effect - a PEARRL review.
O'Shea JP; Holm R; O'Driscoll CM; Griffin BT
J Pharm Pharmacol; 2019 Apr; 71(4):510-535. PubMed ID: 29956330
[TBL] [Abstract][Full Text] [Related]
17. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
Giacoia GP; Taylor-Zapata P; Zajicek A
Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
[TBL] [Abstract][Full Text] [Related]
18. In Vivo Predictive Dissolution Testing of Montelukast Sodium Formulations Administered with Drinks and Soft Foods to Infants.
Martir J; Flanagan T; Mann J; Fotaki N
AAPS PharmSciTech; 2020 Oct; 21(7):282. PubMed ID: 33051713
[TBL] [Abstract][Full Text] [Related]
19. Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system.
Del Moral Sanchez JM; Gonzalez-Alvarez I; Cerda-Revert A; Gonzalez-Alvarez M; Navarro-Ruiz A; Amidon GL; Bermejo M
Br J Clin Pharmacol; 2018 Oct; 84(10):2231-2241. PubMed ID: 29846973
[TBL] [Abstract][Full Text] [Related]
20. Problems with oral formulations prescribed to children: a focus group study of healthcare professionals.
Venables R; Stirling H; Batchelor H; Marriott J
Int J Clin Pharm; 2015 Dec; 37(6):1057-67. PubMed ID: 26173937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
